AmCad BioMed

AmCad BioMed EBIT Margin

The EBIT Margin (Operating Margin) of AmCad BioMed (4188.TWO) as of Nov 2, 2026 is -288.97 %. In the previous year, EBIT Margin (Operating Margin) was -121.77 % — a change of 137.32% (lower).

EBIT Margin

-288.97 %

YoY

137.32%

Last updated:

EBIT Margin (Operating Margin) of AmCad BioMed is 2025 -288.97 % . EBIT Margin (Operating Margin) of AmCad BioMed was 2024 -121.77 % . It decreases by 137.32% lower compared to the previous year.

AmCad BioMed's operating (EBIT) margin stands at -289.0%, down from -31.3% several years earlier.

The AmCad BioMed EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-110.74 TWD
Jan 1, 2019
-66.94 TWD
Jan 1, 2020
-66.99 TWD
Jan 1, 2021
-31.29 TWD
Jan 1, 2022
-88.07 TWD
Jan 1, 2023
-65.93 TWD
Jan 1, 2024
-121.77 TWD
Jan 1, 2025
-288.97 TWD
The AmCad BioMed EBIT Margin history
YEAREBIT MarginYoY
-288.97 %+137.32%
-121.77 %+84.68%
-65.93 %-25.13%
-88.07 %+181.45%
-31.29 %-53.29%
-66.99 %+0.08%
-66.94 %-39.55%
-110.74 %-63.35%
-302.19 %-48.62%
-588.11 %-98.70%
-45,412.77 %+93,178.17%
-48.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

AmCad BioMed Stock analysis

What does AmCad BioMed do? AmCad BioMed Corp, headquartered in Taipei City, Taiwan, specializes in manufacturing and selling medical diagnostic software devices. The company offers products like AmCAT-UT Detection, a computer-aided detection system for thyroid ultrasound, and AmCAD-UT Diagnosis, a computer-aided diagnosis system for the same purpose. Listed on 26 December 2013, AmCad BioMed operates in Taiwan, China, and Hong Kong markets. AmCad BioMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AmCad BioMed stock

EBIT Margin (Operating Margin) of AmCad BioMed is -288.97 % in 2025.

EBIT Margin (Operating Margin) of AmCad BioMed changed from -121.77 % to -288.97 %, representing a 137.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) AmCad BioMed since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s AmCad BioMed with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — AmCad BioMed

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — AmCad BioMed